Hydreight talks up August order growth

Mr. Shane Madden reports HYDREIGHT POSTS RECORD VSDHONE GROWTH AND OUTPERFORMS INTERNAL PROJECTIONS Hydreight Technologies Inc. today provided a corporate update highlighting stronger-than-expected order growth and recent strategic milestones. In August, 2025, Hydreight processed over 80,000 pharmacy and telehealth product orders, surpassing the company's internal forecast of approximately 55,000 product orders. Order growth and market momentum Hydreight's higher-than-expected order volume reflects broad demand across multiple service lines, many of which are among the fastest-growing segments of the United States health care market. The company is also seeing continued expansion in wellness categories including IV therapy, hormone optimization and preventive testing, further diversifying its revenue base. The strong August performance follows a series of structural initiatives undertaken earlier this year to increase capacity and improve patient experience. These included expanding Hydreight's medical director network, enhancing pharmacy integrations for faster fulfilment and further automating the VSDHOne platform to ensure compliance at scale. Other updates: Nurse network growth: From January to August, 2025, Hydreight added 528 new nurse licences, up from 307 in the same period of 2024 -- a 72-per-cent year-over-year increase. Pharmacy order growth: From January to August, 2025, pharmacy orders increased approximately 86 per cent year over year. VSDHOne platform investment: A key focus has been Hydreight's investment in making the VSDHOne platform fully modular, allowing customers to adopt it module by module to fit their specific needs. This flexibility is designed to improve adoption rates and expand Hydreight's total addressable market by meeting providers where they are in their digital health journey. Hydreight reported 33-per-cent year-over-year revenue growth for H1 2025: marking the company's third consecutive quarter of profitability. Performance improved across multiple verticals, supported by strong pharmacy order growth and continued network expansion. Management emphasized disciplined cost control and operational efficiency as key drivers of sustained profitability while investing strategically in technology, compliance and growth initiatives. (Please see SEDAR+ for the company's condensed consolidated audited financial statements and MD&A (management's discussion and analysis) for audited annual consolidated financial statements for the year ended Dec. 31, 2023.) Strategic growth initiatives The company has also advanced several corporate initiatives intended to strengthen its platform and long-term growth trajectory: Oversubscribed financing: On Sept. 4, Hydreight closed an oversubscribed $11.5-million convertible debenture financing, including the full exercise of the overallotment option. Proceeds provide growth capital to finance strategic initiatives, support acquisition integration and strengthen Hydreight's balance sheet. Acquisition of Perfect Scripts stake: On Sept. 2, the company signed a definitive agreement to acquire an initial 5-per-cent equity stake in Perfect Scripts LLC, a licensed 503A pharmacy, with the option to increase ownership up to 40 per cent. The transaction is subject to the exchange approval. This partnership is expected to provide additional operational control over pharmacy fulfillment, support margin expansion and enable the company to scale personalized compounded medications nationwide. AI integration: On Sept. 8, Hydreight entered into a binding letter of intent and is currently in due diligence to acquire Dynamic IV Therapy Support AI agent, an artificial intelligence-driven tool designed to guide providers with personalized IV treatment recommendations. This technology is intended not only to support clinical decision-making but also to serve as a powerful marketing tool for Hydreight's clients. By embedding AI at the point of care, providers can differentiate their services, instill greater patient confidence and highlight their use of advanced technology in delivering personalized wellness solutions. Over time, management believes this capability can help improve patient safety, streamline provider workflows and strengthen the overall value proposition for the thousands of clinics and practitioners operating on Hydreight's platform. Customer lifetime value (LTV) expansion section Beyond one-time order volume, customer lifetime value (LTV) has become a key area of focus for Hydreight, as it is a critical driver of sustainable growth. Many patients initially enter the platform for one high-demand product, but the goal is to then expand their care journey across additional verticals within Hydreight's ecosystem. This expansion pathway is designed to both improve unit economics and deepen patient relationships, creating long-term value for the company and its shareholders. Starting with GLP-1 therapy for weight management, then moving into testosterone replacement therapy (TRT) for energy and performance. Adding hair loss treatments, ED medications, peptide therapies and in some cases antiemetics such as ondansetron, which are commonly prescribed to manage nausea or support patients undergoing broader therapeutic regimens. Extending into at-home genetic or lab testing to support personalized treatment pathways. Outlook While Hydreight is encouraged by its recent order growth and improving LTV metrics, management emphasizes that growth requires continued investment in infrastructure, technology and regulatory compliance. Integration of new acquisitions, while strategically important, will also require execution focus. The company believes that its combination of an established nationwide provider network, expanding pharmacy relationships, growing patient demand and strengthening LTV dynamics provides a differentiated position in the fragmented United States digital health market. Management commentary "Hydreight's performance in August was a clear signal of the growing strength of our platform," said Shane Madden, chief executive officer of Hydreight. "What excites us most is that this momentum is not driven by one product line, but by broad-based adoption across weight management, wellness and longevity care. "Equally important, we're staying disciplined in how we build. That means focusing on the right infrastructure, compliance frameworks and long-term approaches to support sustainable growth. We're committed to scaling responsibly while delivering real value to patients, providers and shareholders. "We've been very deliberate in strengthening our foundation -- whether that's raising growth capital, expanding into pharmacy ownership or bringing AI-driven tools into our ecosystem. These steps are not about short-term wins, but about building a scalable, compliant and sustainable model that can grow with the needs of patients and providers alike." Upcoming investor conferences Hydreight will be participating in the following investor conferences: CEM Muskoka Capital Event Sept. 26 to Sept. 28, 2025 -- Muskoka, Ont. Smallcap Discoveries Investor Event Sept. 29 to Sept. 30, 2025 -- Vancouver, B.C. Planet Microcap Showcase in partnership with MicroCapClub Oct. 21 to Oct. 23, 2025 -- Toronto, Ont. These events provide opportunities for investors to engage directly with Hydreight's management team and learn more about the company's strategy, milestones and outlook. About Hydreight Technologies Inc. Hydreight Technologies is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3,000 nurses, over 200 doctors and a pharmacy network through its doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking and managing patient data, which enables licensed health care professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed health care professionals. The Hydreight platform allows health care professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network. About VSDHOne -- direct-to-consumer platform Developed in partnership with Victory Square Technologies, Hydreight Technologies launched the VSDHOne (read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the on-line health care space compliantly. This platform will help all businesses to launch a direct-to-consumer health care brand in a matter of days in all 50 states. compliant offerings include: GLP-1s, peptides, personalized health care treatments, sermorelin, testosterone replacement therapy (TRT), hair loss, skin care, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer health care brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the on-line health care space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months. We seek Safe Harbor.